{"meta":{"query_hash":"6bcb093c5c3f","filters":{"venue":"Hematology Meeting Reports (formerly Haematologica Reports)"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6bcb093c5c3f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Hematology+Meeting+Reports+%28formerly+Haematologica+Reports%29"},"results":[{"id":"W1554065380","doi":"10.4081/hmr.v3i3.587","title":"Advanced Hodgkin’s lymphoma: doxorubicin, bleomycin, vinblastine, dacarbazine and beyond","year":2009,"lang":"en","type":"article","venue":"Hematology Meeting Reports (formerly Haematologica Reports)","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ABVD; Dacarbazine; Medicine; Vinblastine; Bleomycin; Internal medicine; Oncology; Nuclear medicine; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.008444083112896697,"score_gpt":0.2554773388233663,"score_spread":0.24703325571046963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1554065380","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0407543,0.74230665,0.0013585832,0.05262265,0.01021394,0.0002578685,0.0011856465,0.00028395577,0.15101644],"genre_scores_gemma":[0.20429921,0.5657295,0.0032207558,0.033532236,0.008323848,0.00027705388,0.0028078405,0.00008483643,0.18172474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998273,0.000035453726,0.00002394131,0.000023863215,0.000064148524,0.000025356901],"domain_scores_gemma":[0.9998196,0.000036060323,0.000025886677,0.000010313174,0.000048985054,0.000059274294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006022425,0.00023764843,0.00029844776,0.00037941657,0.00019076369,0.0005555149,0.00017666275,0.00056508824,0.00544765],"category_scores_gemma":[0.00051736267,0.00011526978,0.00016349807,0.00033001645,0.00021315362,0.00054174714,0.00042746883,0.0011827231,0.0018150657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006865595,0.00016971052,0.0021043438,0.00078910455,0.000028503177,0.00040838632,0.00007032269,0.00019999761,0.002595478,0.0030078709,0.10209143,0.8878482],"study_design_scores_gemma":[0.00017982867,0.00048454755,0.010745601,0.0005355798,0.000035201676,0.0011000808,0.000027021739,0.00008026491,0.0007826702,0.0007082188,0.9853086,0.000012384202],"about_ca_topic_score_codex":0.0022357726,"about_ca_topic_score_gemma":0.010939876,"teacher_disagreement_score":0.00544765,"about_ca_system_score_codex":0.00078684563,"about_ca_system_score_gemma":0.0005749418,"threshold_uncertainty_score":0.01822424},"labels":[],"label_agreement":null},{"id":"W1608548877","doi":"10.4081/hmr.v2i5.719","title":"Progress in the management of iron overload in erytrocyte disorders","year":2009,"lang":"en","type":"article","venue":"Hematology Meeting Reports (formerly Haematologica Reports)","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Deferasirox; Deferiprone; Medicine; Thalassemia; Chelation therapy; Deferoxamine; Regimen; Neutropenia; Beta thalassemia; Internal medicine; Blood transfusion; Anemia; Pediatrics; Toxicity","score_opus":0.007839992710516944,"score_gpt":0.26218740173067917,"score_spread":0.25434740902016223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1608548877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032405737,0.9826853,0.003606278,0.004101255,0.000636065,0.000037519352,0.000046618487,0.000061983796,0.0055843596],"genre_scores_gemma":[0.029313968,0.952585,0.009367956,0.0024874033,0.0031471325,0.00008073449,0.00024412671,0.000030586307,0.0027431317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994128,0.000171996,0.000097416676,0.00008447426,0.000174234,0.000059117596],"domain_scores_gemma":[0.9991732,0.00030002175,0.00014583803,0.00004251076,0.00022190255,0.00011646632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013214011,0.0006449626,0.00075381174,0.0011020656,0.00033578844,0.0010469636,0.0008946288,0.0008686474,0.0031810936],"category_scores_gemma":[0.001594054,0.00012992584,0.0007537061,0.0007100858,0.0004803075,0.0010713199,0.00080948434,0.002190313,0.0015297141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025200803,0.00029132888,0.0012192462,0.0034399668,0.00007727556,0.00090451277,0.00013776608,0.0004109932,0.0022617856,0.002795636,0.012850412,0.97535896],"study_design_scores_gemma":[0.00022417701,0.0011988682,0.007011414,0.006325046,0.00037743404,0.012444568,0.00030680606,0.001096389,0.0031160621,0.0060444237,0.96180046,0.00005429856],"about_ca_topic_score_codex":0.0010849972,"about_ca_topic_score_gemma":0.0011383449,"teacher_disagreement_score":0.0031810936,"about_ca_system_score_codex":0.0005491072,"about_ca_system_score_gemma":0.0011686756,"threshold_uncertainty_score":0.010641813},"labels":[],"label_agreement":null}]}